Modulation of P-glycoprotein-mediated efflux by prodrug derivatization: An approach involving peptide transporter-mediated influx across rabbit cornea

被引:46
作者
Katragadda, S [1 ]
Talluri, RS [1 ]
Mitra, AK [1 ]
机构
[1] Univ Missouri, Sch Pharm, Div Pharmaceut Sci, Kansas City, MO 64110 USA
关键词
D O I
10.1089/jop.2006.22.110
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
The aim of this study was to investigate the modulation of efflux mechanisms using transporter-targeted prodrug derivatization of a model P-gp substrate, quinidine. The L-valine, L-valine-valine esters of quinidine, val-quinidine (VQ), and val-val-quinidine (VVQ) were synthesized in our laboratory, respectively. [C-14] erythromycin was chosen to delineate the affinity of quinidine (Q) toward p-gp. [H-3] glycylsarcosine (GS, or glysar) was chosen as a model peptide transporter (PEPT) substrate. Uptake studies were performed on rPCEC (rabbit primary corneal epithelial culture) using 12-well plates. Transport studies were conducted with isolated rabbit corneas at 34 degrees C. Efflux of [C-14] erythromycin was significantly increased in the presence of quinidine, whereas it was unaltered in the presence of VQ and VVQ. VVQ was more stable, both in buffers and tissue homogenate. Transport of VQ and VVQ was inhibited with GS, and their permeability values were 1.5 and 3 times higher than the permeability of quinidine, respectively. Results from this study clearly indicate that prodrug derivatization of quinidine can modulate P-gp-mediated efflux. These prodrugs have a reduced or diminished affinity toward P-gp and were further recognized by the peptide transporter-mediated process. Enhanced permeabilities of the prodrugs indicate that drug derivatization can be a viable strategy for overcoming P-gp-mediated efflux.
引用
收藏
页码:110 / 120
页数:11
相关论文
共 42 条
[1]  
Agata M, 1984, Nippon Ganka Gakkai Zasshi, V88, P991
[2]   Mechanism of corneal permeation of L-valyl ester of acyclovir: Targeting the oligopeptide transporter on the rabbit cornea [J].
Anand, BS ;
Mitra, AK .
PHARMACEUTICAL RESEARCH, 2002, 19 (08) :1194-1202
[3]   Novel dipeptide prodrugs of acyclovir for ocular herpes infections: Bioreversion, antiviral activity and transport across rabbit cornea [J].
Anand, BS ;
Nashed, YE ;
Mitra, AK .
CURRENT EYE RESEARCH, 2003, 26 (3-4) :151-163
[4]   In vivo antiviral efficacy of a dipeptide acyclovir prodrug, val-val-acyclovir, against HSV-1 epithelial and stromal keratitis in the rabbit eye model [J].
Anand, BS ;
Hill, JM ;
Dey, S ;
Maruyama, K ;
Bhattacharjee, PS ;
Myles, ME ;
Nashed, YE ;
Mitra, AK .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 (06) :2529-2534
[5]   The distribution of the HIV protease inhibitor, ritonavir, to the brain, cerebrospinal fluid, and choroid plexuses of the guinea pig [J].
Anthonypillai, C ;
Sanderson, RN ;
Gibbs, JE ;
Thomas, SA .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 308 (03) :912-920
[6]   Identification of a novel system L amino acid transporter structurally distinct from heterodimeric amino acid transporters [J].
Babu, E ;
Kanai, Y ;
Chairoungdua, A ;
Kim, DK ;
Iribe, Y ;
Tangtrongsup, S ;
Jutabha, P ;
Li, YW ;
Ahmed, N ;
Sakamoto, S ;
Anzai, N ;
Nagamori, S ;
Endou, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (44) :43838-43845
[7]   Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir [J].
Balimane, PV ;
Tamai, I ;
Guo, AL ;
Nakanishi, T ;
Kitada, H ;
Leibach, FH ;
Tsuji, A ;
Sinko, PJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 250 (02) :246-251
[8]  
Balimane PV, 2000, BIOPHARM DRUG DISPOS, V21, P165, DOI 10.1002/1099-081X(200007)21:5<165::AID-BDD225>3.0.CO
[9]  
2-F
[10]  
BAUM J, 1983, OPHTHALMOLOGY, V90, P162